Shilpa Medicare is currently trading at Rs. 361.35, up by 10.05 points or 2.86% from its previous closing of Rs. 351.30 on the BSE.
The scrip opened at Rs. 358.25 and has touched a high and low of Rs. 363.40 and Rs. 358.25 respectively. So far 215 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 546.95 on 14-Sep-2018 and a 52 week low of Rs. 335.00 on 19-Feb-2019.
Last one week high and low of the scrip stood at Rs 363.40 and Rs. 335.00 respectively. The current market cap of the company is Rs. 2864.04 crore.
The promoters holding in the company stood at 53.80%, while Institutions and Non-Institutions held 32.35% and 13.85% respectively.
Shilpa Medicare has received US Food and Drug Administration’s (USFDA) approval for its ANDA, Gemcitabine for Injection USP, 200 mg/vial and 1 g/vial. Gemcitabine for Injection USP is a generic equivalent of reference listed drug (RLD), GEMZAR used in the treatment of ovarian cancer, breast cancer, non-small cell lung cancer & pancreatic cancer as recommended in the label approved by USFDA.
According to IQVIA MAT 12/2018, the US market for Gemcitabine for Injection USP, 200 mg/vial and 1 g/vial is approximately $11.7 million.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
